This study is testing a drug called firmonertinib against standard treatments (osimertinib or afatinib) for people with advanced non-small cell lung cancer (NSCLC). Your cancer must have a specific change in the EGFR gene called a PACC mutation, which will be checked through a biopsy or blood test. The study aims to see if firmonertinib can slow down cancer growth or shrink tumors more effectively than current treatments. Researchers will compare how long people live without their cancer getting worse (progression-free survival) and how many people see their tumors shrink (overall response rate). This is for people who have not had other treatments for their advanced NSCLC.

Study design

This is a global, Phase 3 study where participants will be randomly assigned to receive either firmonertinib or one of the standard treatments. About 480 people are planned to join this study.

What's involved

Participants will take their assigned medication (firmonertinib, osimertinib, or afatinib) as a daily oral tablet. The study will assess outcomes for up to approximately 4 years.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow participants until their cancer progresses or they pass away, with assessments for progression-free survival up to approximately 4 years and overall response rate up to approximately 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.